replicateBE: Average Bioequivalence with Expanding Limits (ABEL)
Performs comparative bioavailability calculations for Average
Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' /
'Method B' and the detection of outliers. If the design allows, assessment
of the empiric Type I Error and iteratively adjusting alpha to control the
consumer risk. Average Bioequivalence - optionally with a tighter (narrow
therapeutic index drugs) or wider acceptance range (South Africa: Cmax) -
is implemented as well.
Version: |
1.1.3 |
Depends: |
R (≥ 3.5.0) |
Imports: |
readxl (≥ 1.0.0), PowerTOST (≥ 1.5.3), lmerTest, nlme, pbkrtest, graphics, grDevices |
Suggests: |
knitr, rmarkdown, testthat, devtools |
Published: |
2022-05-02 |
Author: |
Helmut Schütz
[aut, cre],
Michael Tomashevskiy [ctb],
Detlew Labes
[ctb] |
Maintainer: |
Helmut Schütz <helmut.schuetz at bebac.at> |
BugReports: |
https://github.com/Helmut01/replicateBE/issues |
License: |
GPL (≥ 3) |
URL: |
https://github.com/Helmut01/replicateBE |
NeedsCompilation: |
no |
Materials: |
README NEWS |
In views: |
ClinicalTrials |
CRAN checks: |
replicateBE results |
Documentation:
Downloads:
Linking:
Please use the canonical form
https://CRAN.R-project.org/package=replicateBE
to link to this page.